There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Most recently, Yahoo Finance reported about the stock as it publicized that Medicenna Strengthens Intellectual Property Protection for MDNA11 and BiSKITs™ Programs with Issuance of U.S. Patent.
As a NASDAQ listed company, MDNA falls under the Healthcare sector while operating within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $0.60 and fluctuated between $0.6201 as its day high and $0.5799 as its day low. The current market capitalization of Medicenna Therapeutics Corp. is $56.40M. A total of 66446.0 shares were traded on the day, compared to an average of 169.03K shares.
Aside from predicting where a stock will go, investors also consider insider trades as an indicator of the stock’s future direction. During the recent three months, MDNA has seen 0 BUY and 2 SELL insider trades, representing the acquisition of 0 and the disposition of 112,500 shares. Over the last 12 months, there were 12 BUYs and 2 SELLs from insiders. Insiders purchased 121,000 shares during that period but sold 112,500.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. According to analysts who have offered 12-month price targets for MDNA in the last 3 months, the mean price target is $3.52 with high estimates of $8.00 and low estimates of $1.46. In terms of 52-week highs and lows, MDNA has a high of $2.00 and a low of $0.40.
As of this writing, MDNA has an earnings estimate of -$0.05 per share for the current quarter. EPS was calculated based on a consensus of 3 estimates, with a high estimate of -$0.04 per share and a lower estimate of -$0.05. The company reported an EPS of -$0.04 in the last quarter, which was 50.00% higher than expectations of -$0.08.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 6 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for MDNA is Overweight with a score of 5.00. A total of 6 analysts rated the stock as Buy while 0 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.